Jake Adams - CRB - The Future of ATMPs

ATMPs...or Advanced Therapeutic Medicinal Products, are the "next big thing" in the world of #Pharma. If you are in the space, the big ones you hear most about are Cell & Gene Therapy and...lately...mRNA vaccines (thank you COVID-19).   This world isn't as simple as 2 or 3 therapies...it's more than that. Investment in Cell&Gene Therapy has been setting records with $20 and $23 Billion in the last 2 years alone. This is kind of a big deal.  Jake Adams, from CRB, joins me to discuss this and also the world of #RNA modulating therapies (not all as well known as mRNA Vaccines).    We discuss what makes these different therapies unique, what makes them effective, and more. Also a few rabbit trails including how did Jake turn into a go-to man for RNA as a young engineer. So listen up... :)   Check at Jake on LinkedIn!   Subscribe to our channel! Want to learn more about investment into the Cell & Gene Space? CGT 2022 Investment Outlook Learn about Oligonucleotides HERE! Quick overview about TPDs HERE!

Om Podcasten

The Modern BioPharma Podcast was born out of the 2020 COVID-19 Pandemic and the desire to connect professionals in the pharmaceutical engineering community to the stories of others around them and what they are doing to make a difference. This industry is one of resistance to change all while life altering medicines and therapies are coming into existence that demand a different kind of manufacturing plant. The same people work on these facilities across the industry. Let's get to know each other.